Comparableroles of CD44v8–10 and CD44s in the developmentof bone metastases in a mouse model. by HIRAGA TORU & NAKAMURA HIROAKI
ONCOLOGY LETTERS  12:  2962-2969,  20162962
Abstract. Cluster of differentiation (CD)44 has been impli-
cated in cancer metastasis to bone. Clinical and experimental 
studies have suggested that the standard isoform of CD44 
(CD44s) and the variant isoform of CD44 (CD44v) enhance 
metastasis. The present study examined the differential roles 
of CD44s and CD44v, particularly CD44v8-10, in the devel-
opment of bone metastases. For this purpose, MDA-MB-231 
human breast cancer cells and A549 human lung cancer cells 
were stably transduced with epithelial splicing regulatory 
protein 1 (ESRP1), which regulates the alternative splicing of 
several genes, including CD44. The introduction of ESRP1 
induced a splicing switch from CD44s to CD44v, particularly 
to CD44v8-10, while the total amount of CD44 was rarely 
affected. However, ESRP1 did not significantly affect cell 
proliferation, migration, invasion or tumor sphere formation 
in vitro. Furthermore, ESRP1 did not cause significant differ-
ences in the development of bone metastases in a mouse 
model. As an alternative approach, cancer cells transduced 
with the CD44v8-10 gene were also established. The overex-
pression of CD44v8-10 in MCF-7 human breast cancer cells, 
which rarely express any isoform of CD44, promoted cell 
migration and sphere formation, whereas the overexpression 
of CD44v8-10 in MDA-MB-231 cells, which endogenously 
express high levels of CD44s, did not exert these effects. 
The results of the present study collectively suggest that the 
ability of CD44v8-10 to promote tumor aggressiveness and 
bone metastases is similar to that of CD44s. CD44v8-10 and 
CD44s may represent potential therapeutic targets for the 
treatment of bone metastases.
Introduction
Cluster of differentiation (CD)44 is a transmembrane glyco-
protein that functions as an adhesion molecule for extracellular 
matrices, primarily hyaluronan (1,2). The expression of CD44 
in cancer cells has also been implicated in cell migration, 
invasion and metastasis (1,2). Furthermore, CD44 has recently 
been recognized as a major marker for cancer stem cells 
(CSCs) in several types of cancer (2,3).
The CD44 gene consists of 20 exons, 10 of which 
(exons 1-5 and 16-20) encode the shortest and ubiquitously 
expressed standard isoform of CD44 (CD44s) (1,2). The 
other 10 exons (exons 6-15, also referred to as exons v1-v10) 
are variant exons inserted by alternative splicing in various 
combinations, thereby generating various variant isoforms 
of CD44 (CD44v) (1,2). The insertion of variant exons 
lengthens the extracellular domain and alters the binding and 
signaling properties of CD44. The expression of CD44v is 
restricted to a few epithelial tissues, including several types of 
cancer (2). Although extensive research has been conducted, 
the association between the expression of CD44v and tumor 
aggressiveness remains controversial (1,2,4-6).
CD44v8-10, also known as CD44R1 and CD44E, is one of 
the isoforms of CD44v, and contains the variant exons 13-15 
(v8-v10) (1,2). Clinical studies have demonstrated that 
CD44v8-10 is expressed in various human epithelial cancers, 
including breast, lung, colon, bladder and gastric cancer, and 
its expression is correlated with metastasis (7-10). Further-
more, recent studies suggest that the expression of CD44v8-10 
is associated with CSC-like phenotypes (11,12).
The bone is one of the most frequent organs to be affected 
by metastatic cancer (13). Bone metastases cause devastating 
bone pain and skeletal-related events, including pathological 
fractures, spinal compression and hypercalcemia, thereby 
severely deteriorating the quality of life of patients (13). 
However, the mechanisms underlying bone metastases have 
not yet been fully elucidated.
Clinical studies have suggested that a positive correla-
tion exists between the expression of CD44 and bone 
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metastasis (14,15). Furthermore, our recent preclinical study 
demonstrated that CD44, particularly CD44s, confers CSC-like 
properties to cancer cells and enhances their metastatic 
potential to bone (16). However, the roles of CD44v in the 
development of bone metastases have yet to be explored. Thus, 
the present study examined the differential roles of CD44s and 
CD44v, particularly CD44v8-10, in bone metastases using a 
well-characterized animal model.
Materials and methods
Cell cultures. The human breast cancer cell lines MDA-MB-231 
and MCF-7 were obtained from the American Type Culture 
Collection (Manassas, VA, USA). The human lung cancer cell 
line A549 was obtained from the Health Science Research 
Resources Bank (Osaka, Japan). Cells were cultured in Dulbec-
co's modified Eagle's medium (DMEM; Sigma-Aldrich; Merck 
Millipore, Darmstadt, Germany) supplemented with 10% fetal 
bovine serum (FBS; Thermo Fisher Scientific, Inc., Waltham, 
MA, USA) and 100 µg/ml kanamycin sulfate (Meiji Seika 
Kaisha, Ltd., Tokyo, Japan), and were maintained at 37˚C in a 
humidified atmosphere of 5% CO2 in air.
Overexpression of ESRP1 and CD44v8-10. The comple-
mentary (c)DNA of human epithelial splicing regulatory 
protein 1 (ESRP1) in the pOTB7 vector was purchased from 
Dharmacon (GE Healthcare Bio-Sciences, Pittsburgh, PA, 
USA). Human CD44v8-10 cDNA was reverse transcribed and 
amplified from total RNA isolated from MDA-MB-231 cells 
overexpressing the ESRP1 gene. Total RNA was isolated using 
a High Pure RNA Isolation kit (Roche Diagnostics, Basel, 
Switzerland). cDNA was synthesized from 5 µg of total RNA 
using PrimeScript Reverse Transcriptase (Takara Bio, Inc., 
Shiga, Japan). The primer sequences for CD44v8-10 were 
5'-CGG ACA CCA TGG ACA AGT TT-3' (forward) and 5'-TCC 
AAC GGT TGT TTC TTT CC-3' (reverse). PCR was performed 
using PrimeSTAR GXL DNA polymerase (Takara Bio, Inc.) 
with a TaKaRa PCR Thermal Cycler Dice (Takara Bio, Inc.) 
for 30 cycles (98˚C for 10 sec, 60˚C for 15 sec and 68˚C for 
90 sec). Both cDNAs were subcloned into the pLVSIN-CMV 
Pur vector (Takara Bio, Inc.) and transduced into cells using 
a Lenti-X Lentiviral Expression System (Takara Bio, Inc.). 
As a control, empty vector (EV) was transduced into the 
cells. Colonies resistant to puromycin (0.25-1.00 µg/ml; 
Sigma-Aldrich; Merck Millipore) were isolated and cloned.
Reverse transcription-polymerase chain reaction (RT-PCR). 
Total cellular RNA was isolated using a High Pure RNA 
Isolation kit. cDNA was synthesized from 5 µg of total 
RNA using PrimeScript Reverse Transcriptase. Two sets 
of PCR primers were used to detect CD44 (8). One set 
(primer set 1, forward 5'-TCC CAG ACG AAG ACA GTC CCT 
GGAT-3' and reverse 5'-CAC TGG GGT GGA ATG TGT CTT 
GGTC-3') detected all the isoforms of CD44, while the 
other set (primer set 2, forward 5'-GAC AGA ATC CCT GCT 
ACC AATA-3' and reverse 5'-ATG TGT CTT GGT CTC CTG 
ATAA‑3') specifically detected CD44v8-10 and CD44v10. 
The primer sequences for glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) were 5'-CAT GGA GAA GGC TGG 
GGC TC-3' (forward) and 5'-CAC TGA CAC GTT GGC AGT 
GG-3' (reverse). PCR was conducted using PCR Master Mix 
(Promega Corporation, Madison, WI, USA) with a TaKaRa 
PCR Thermal Cycler Dice for 25 cycles (at 95, 55 and 72˚C 
for 30 sec), or for 20 cycles in the case of GAPDH. The PCR 
products were separated on 2% agarose gels containing 
ethidium bromide and visualized under UV light. The sizes 
of the fragments were confirmed by comparison with a 
100-bp DNA ladder (Takara Bio, Inc.).
Flow cytometry. Cells were harvested by trypsinization and 
incubated with a phycoerythrin (PE)-conjugated anti-panCD44 
antibody (1:100 dilution; 12-0441-81; eBioscience, Inc., San 
Diego, CA, USA) for 40 min at 4˚C. Flow cytometric analysis was 
performed using a flow cytometer (Cytomics FC 500; Beckman 
Coulter, Inc., Brea, CA, USA). Data were analyzed using FlowJo 
software (version 7.6.5; FlowJo, LLC, Ashland, OR, USA).
Western blotting. Total protein lysates were prepared in lysis 
buffer [20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (pH 7.4), 150 mM NaCl, 1 mM ethylene glycol-bis(β-
aminoethyl ether)-N,N,N',N'-tetraacetic acid, 1.5 mM MgCl2, 
10% glycerol, 1% Triton X-100, 10 µg/ml aprotinin, 10 µg/ml 
leupeptin, 1 mM phenylmethylsulfonyl fluoride and 0.2 mM 
sodium orthovanadate]. Equal amounts of proteins were 
separated on 7.5% sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis and transferred onto nitrocellulose 
membranes (Bio-Rad Laboratories, Inc., Hercules, CA, USA). 
The membranes were then immunoblotted with the following 
antibodies: Anti-panCD44 [1:500 dilution (17)], anti-CD44v9 
(1:500 dilution; LKG-M001; Cosmo Bio, Tokyo, Japan), 
anti-ESRP1 (1:500 dilution; HPA023720; Atlas Antibodies 
AB, Stockholm, Sweden) and anti-β-actin (1:1,000 dilution; 
A00702; GenScript, Tokyo, Japan), and visualized with a 
horseradish peroxidase-conjugated anti-mouse immuno-
globulin (Ig)G (1:10,000 dilution; 715-035-150; Jackson 
ImmunoResearch Laboratories, Inc., West Grove, PA, USA) 
or anti-rabbit IgG antibody (1:10,000 dilution; 711-035-152; 
Jackson ImmunoResearch Laboratories, Inc.), followed by 
enhanced chemiluminescence (ECL). ECL solution was 
made by dissolving 0.2 mM p-coumaric acid (Sigma-Aldrich; 
Merck Millipore), 2.5 mM luminol (Sigma-Aldrich; Merck 
Millipore) and 0.02% hydrogen peroxide (Wako Pure 
Chemical Industries, Ltd., Osaka, Japan) in 100 mM Tris-HCl 
(pH 8.5). The expression of β-actin was used as a loading 
control.
Cell proliferation in monolayer cultures. Cells (1,000 cells/well) 
were plated in a 96-well plate in growth medium and cultured 
for 72 h. Subsequently, cell proliferation was determined using 
Cell Proliferation Reagent WST-1 (Roche Diagnostics). Absor-
bance was measured using iMark Microplate Absorbance 
Reader (Bio-Rad Laboratories, Inc.) at a wavelength of 450 nm.
Wound healing assay. Cells (1x105 cells/well) were plated in a 
24-well plate in growth medium and incubated for 24 h. Upon 
confirming the formation of a complete monolayer, cells were 
wounded by scratching lines with a standard 200-µl plastic 
pipette tip. Cell migration into the wound area was observed 
with a phase-contrast microscope after 24 or 48 h. The 
percentage of the filled wound area was calculated as follows: 
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Filled wound area (%) = (original wound area-remaining 
wound area)/original wound area x 100.
Cell invasion assay. Cell invasion assays were conducted using 
24-well Corning BioCoat Matrigel Invasion Chambers (BD 
Biosciences, Franklin Lakes, NJ, USA). In brief, cells were 
seeded into the upper inserts (2.5x104 cells/insert) in DMEM 
supplemented with 1% FBS. The outer wells were filled with 
DMEM containing 10% FBS as a chemoattractant. After 
24-h incubation, the membranes were stained with hema-
toxylin and mounted on slides. Invading cells were counted in 
five randomly selected microscopic fields. Data are expressed 
as the number of invaded cells/field.
Tumor sphere formation. Cells were plated in ultra-low 
attachment 24-well plates (Corning, Inc., Corning, NY, 
USA) at a density of 1,000 cells/well and cultured in 
DMEM/F12 (Sigma-Aldrich; Merck Millipore) supple-
mented with 2% MACS Supplement B27 PLUS (Miltenyi 
Biotec GmbH, Bergisch Gladbach, Germany), 40 ng/ml 
recombinant human fibroblast growth factor-2 (ProSpec, 
East Brunswick, NJ, USA) and 20 ng/ml recombinant 
human epidermal growth factor (Sigma-Aldrich; Merck 
Millipore). The cells were replenished with fresh medium 
every 3 days. After culturing for 6-12 days, the number of 
tumor spheres with a diameter of >100 µm was counted 
by light microscopy. Data are expressed as the number of 
tumor spheres/well.
Animal experiments. Under anesthesia with pentobarbital 
(0.05 mg/g body weight; Kyoritsu Seiyaku Corporation, 
Tokyo, Japan), MDA-MB-231 cell clones [1x105 cells/0.1 ml 
Figure 1. Establishment of MDA-MB-231 and A549 cell clones overexpressing ESRP1. (A) The expression of panCD44, CD44v9 and ESRP1 was deter-
mined by western blot analysis (asterisk, CD44s; arrow, CD44v8-10). Two ESRP1-overexpressing clones (clones 1 and 2) of each cell line were examined 
in subsequent experiments, and compared with empty vector mock-transduced cells. (B) Messenger RNA expression of CD44 was determined by reverse 
transcription‑polymerase chain reaction using two sets of primers. Primer set 1 detected all isoforms of CD44, while primer set 2 specifically detected 
CD44v8-10 and CD44v10. (C) Flow cytometric analysis of the total amount of CD44 protein was determined using an anti-panCD44 antibody. WB, western 
blot; CD, cluster of differentiation; CD44v, variant isoform of CD44; ESRP1, epithelial splicing regulatory protein 1; EV, empty vector; Cl, clone; CD44s, 
standard isoform of CD44; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; PE, phycoerythrin; Ig, immunoglobulin.
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phosphate-buffered saline (PBS)] were injected into the left 
cardiac ventricle of athymic nude mice (KSN/Slc, female, 
4-week-old, n=5/group; Japan SLC, Inc., Shizuoka, Japan). 
All mice were sacrificed 4 weeks after cell inoculation. All 
animal experiments were approved by the Animal Manage-
ment Committee of Matsumoto Dental University (Nagano, 
Figure 2. Cell migration, cell invasion and tumor sphere formation of MDA-MB-231 and A549 cell clones overexpressing ESRP1. (A and B) Cell migration 
of (A) MDA-MB-231 and (B) A549 clones was determined by wound healing assay. Representative microscopic images at 0 and 24 h after wounding are 
shown on the left side of the panel (scale bar, 500 µm). Data are expressed as the percentage of filled wound area. (C and D) Cell invasion of (C) MDA-MB-231 
and (D) A549 clones was determined by matrigel invasion assay. Representative microscopic images of membranes are shown on the left side of the panel 
(scale bar, 200 µm). Data are expressed as the number of cells invaded/field. (E and F) Tumor sphere formation of (E) MDA-MB-231 and (F) A549 clones in 
suspension cultures. Representative microscopic images are shown on the left side of the panel (scale bar, 200 µm). Data are expressed as the number of tumor 
spheres/well. n.s., not significant; CD, cluster of differentiation; ESRP1, epithelial splicing regulatory protein 1; EV, empty vector; Cl, clone.
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Japan). Mice were housed at 28˚C in a 12‑h light:dark cycle 
and were fed and watered ad libitum.
Histomorphometric and immunohistochemical analyses
Histomorphometry. Paraffin sections were prepared by 
conventional methods and were stained with hematoxylin 
and eosin. Histomorphometric analysis of the tumor burden 
in bone was conducted as described previously (16). Data are 
expressed as the tumor area (mm2).
Immunohistochemistry. Paraffin sections were deparaf-
finized in xylene and rehydrated in a graded series of ethanol. 
Endogenous peroxidase activity was blocked by immersing 
the sections in 0.3% H2O2 in methanol for 15 min. After 
blocking with 3% bovine serum albumin in PBS for 30 min, 
sections were incubated with primary antibodies overnight at 
4˚C. Primary antibodies against panCD44 (17) and CD44v9 
(LKG-M001; Cosmo Bio) were applied at a dilution of 1:500. 
Indirect immunohistochemical staining was performed using 
a Histofine Simple Stain MAX PO kit (Nichirei Biosciences, 
Inc., Tokyo, Japan). Chromogen was developed using Liquid 
DAB+ (Dako, Glostrup, Denmark). The slides were counter-
stained with hematoxylin.
Statistical analysis. Data are expressed as the mean ± standard 
error of the mean. Data were analyzed by analysis of variance 
followed by a Tukey's test for determining differences between 
the groups, using Mini StatMate software (version 1.1; ATMS, 
Tokyo, Japan). P<0.05 was considered to indicate a statistically 
significant difference.
Results
Effects of ESRP1 overexpression on bone metastases. ESRP1 
is an epithelial-specific splicing factor that regulates the alter-
native splicing of several genes, including CD44 (18-20). The 
overexpression of ESRP1 has been reported to cause a splicing 
switch from CD44s to CD44v (18-20). In order to examine the 
differential roles of CD44s and CD44v8-10 in bone metastases, 
the current study employed an approach in which the ESRP1 
gene was stably transduced into MDA-MB-231 human breast 
cancer cells and A549 human lung cancer cells (MDA/ESRP1 
and A549/ESRP1, respectively). While mock-transduced cells 
(MDA/EV and A549/EV) predominantly expressed CD44s, 
the overexpression of ESRP1 reduced the expression of 
CD44s, but increased that of CD44v (Fig. 1A). RT-PCR anal-
ysis confirmed that the dominant isoform of CD44v expressed 
Figure 3. Effects of ESRP1 overexpression on the development of bone 
metastases of MDA-MB-231 cells. (A) Representative histological pictures 
of bone metastases (hematoxylin and eosin staining; scale bar, 1 mm). 
(B) Histomorphometric analysis of the tumor burden in bone. Data are 
expressed as tumor area (mm2; n=5/group). (C) Immunohistochemical detec-
tion of the expression of panCD44 and CD44v9 in cancer cells colonized 
in bone (asterisk, bone; scale bar, 100 µm). CD, cluster of differentiation; 
CD44v, variant isoform of CD44; ESRP1, epithelial splicing regulatory 
protein 1; EV, empty vector; Cl, clone; T, tumor; BM, bone marrow; n.s., not 
significant. 
Figure 4. Establishment of MDA-MB-231 and MCF-7 cell clones over-
expressing CD44v8-10. The expression of panCD44 and CD44v9 was 
determined by western blot analysis (asterisk, CD44s; arrow, CD44v8-10). 
MCF-7 cells overexpressing CD44s were also established. WB, western blot; 
CD, cluster of differentiation; CD44v, variant isoform of CD44; EV, empty 
vector; Cl, clone; CD44s, standard isoform of CD44.
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in MDA/ESRP1 and A549/ESRP1 cells was CD44v8-10 
(Fig. 1B). Flow cytometric analysis using an antibody that 
recognizes panCD44 revealed that the total amount of CD44 
expressed was rarely affected by ESRP1 (Fig. 1C).
Using these clones, cellular functions were evaluated by 
in vitro assays. WST-1 assay revealed no significant differences 
in cell proliferation between mock- and ESRP1-transduced 
cells (data not shown). In addition, ESRP1 did not significantly 
affect cell migration or invasion, as determined in wound 
healing and matrigel invasion assays, respectively (Fig. 2A-D). 
Since CD44 is a widely recognized marker for CSCs (2,3), 
CSC-like properties were assessed by sphere formation assay. 
The ability of ESRP1-overexpressing cells to form tumor 
spheres in suspension cultures was similar to that of the control 
cells (Fig. 2E and F).
The bone-metastatic potential of MDA/ESRP1 cells 
in vivo was examined using the intracardiac injection model. 
In accordance with the data obtained in vitro, ESRP1 did not 
Figure 5. Cell migration, cell invasion and tumor sphere formation of MDA-MB-231 and MCF-7 cell clones overexpressing CD44v8-10. (A and B) Cell migra-
tion of (A) MDA-MB-231 and (B) MCF-7 clones was determined by wound healing assay. Representative microscopic images at 0 and 24 h (MDA-MB-231) or 
48 h (MCF-7) after wounding are shown on the left side of the panel (scale bar, 500 µm). Data are expressed as the percentage of filled wound area. **P<0.01, 
***P<0.001 vs. control. (C and D) Cell invasion of (C) MDA-MB-231 and (D) MCF-7 clones was determined by matrigel invasion assay. Representative 
microscopic images of membranes are shown on the left side of the panel (scale bar, 200 µm). Data are expressed as the number of cells invaded/field. 
(E and F) Tumor sphere formation of (E) MDA-MB-231 and (F) MCF-7 clones in suspension cultures. Representative microscopic images are shown on the 
left side of the panel (scale bar, 200 µm). Data are expressed as the number of tumor spheres/well. *P<0.05, **P<0.01, ***P<0.001 vs. control. n.s., not significant; 
CD, cluster of differentiation; CD44v, variant isoform of CD44; EV, empty vector; Cl, clone; CD44s, standard isoform of CD44.
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cause significant differences in the development of bone metas-
tases (Fig. 3A and B), although the expression of CD44v8-10 
in MDA/ESRP1 cells was maintained at a high level in bone 
(Fig. 3C).
Effects of CD44v8-10 overexpression on bone metastases. 
To further examine the roles of CD44v8-10, an alternative 
approach was undertaken in which the CD44v8-10 gene 
was stably transduced into MDA-MB-231 cells to generate 
MDA/CD44v cells (Fig. 4). MDA/CD44v cells exhibited no 
significant changes in cell proliferation, migration, invasion or 
tumor sphere formation in vitro (Fig. 5A, C and E), or in the 
development of bone metastases in mice (Fig. 6).
The effects of the overexpression of CD44v8-10 were 
similarly tested in MCF-7 human breast cancer cells 
(MCF-7/CD44v; Fig. 4). In contrast to MDA-MB-231 and A549 
cells, MCF-7 cells expressed very low levels of any isoform 
of CD44 (Fig. 4). As reported previously (16), the overexpres-
sion of CD44s promoted cell migration and sphere formation 
in MCF-7 cells in vitro (Fig. 5B and F). MCF-7/CD44v also 
exhibited enhanced cell migration and sphere formation 
compared with the control cells (Fig. 5B and F), while neither 
CD44s nor CD44v8-10 stimulated cell invasion (Fig. 5D). 
MCF-7 cells have been demonstrated to possess low metastatic 
potential and rarely metastasize to bone (16). Our previous 
study revealed that overexpression of CD44s did not enhance 
the development of bone metastases (16). Similarly, in the 
present study, overexpression of CD44v8-10 failed to poten-
tiate metastatic potential and developed few lesions in bone 
(data not shown).
Discussion
Accumulating evidence indicates that CD44 is involved in 
various cancer phenotypes, including enhanced cell prolif-
eration, migration, invasion and metastasis (1,2). Consistent 
with these findings, the present authors recently reported that 
the expression of CD44 in cancer cells increases tumorige-
nicity, cell migration and invasion, thereby promoting cancer 
metastasis to bone (16). However, it currently remains unknown 
whether CD44s and CD44v make differential contributions to 
the development of bone metastases.
Similar to the overexpression of CD44s, that of CD44v8-10 
in MCF-7 cells (which rarely express any isoforms of CD44) 
significantly increased cell migration and tumor sphere forma-
tion. These results suggest that CD44v8-10 has the potential to 
promote tumor progression in a similar manner to CD44s. The 
overexpression of ESRP1, which caused a switch in alternative 
splicing from CD44s to CD44v (mainly CD44v8-10) did not 
change the phenotypes or metastatic potential of MDA-MB-231 
or A549 cells. Considering that ESRP1 did not change the 
total amount of CD44, the contribution of CD44v8-10 to the 
development of bone metastases is likely comparable to that 
of CD44s. However, the overexpression of CD44v8-10 did not 
further enhance the aggressiveness of MDA-MB-231 cells. 
Since MDA-MB-231 cells endogenously express high level of 
CD44s, the efficacy of endogenous CD44s to enhance bone 
metastases may have already reached its maximum level.
As discussed above, although cell migration and tumor 
sphere formation were stimulated in MCF-7/CD44v cells, 
these effects were less prominent than those observed in 
MCF-7/CD44s cells (Fig. 5B and F). One explanation for these 
results is that the expression levels of CD44s and CD44v8-10 
may not be completely the same. Another possibility is that there 
are functional differences between CD44s and CD44v8-10. 
CD44s has been demonstrated to interact with its major 
ligand, hyaluronan, more effectively than CD44v8-10 (21). In 
addition, the CD44v segment is known to include binding sites 
for several growth factors (2). These differences may become 
visible under certain conditions.
Our previous study revealed that the overexpression of 
CD44s in MCF-7 cells failed to increase bone metastases, 
although cell migration and tumorigenicity were signifi-
cantly enhanced (16). Similar results were obtained with 
MCF-7/CD44v cells, suggesting that solely CD44v8-10 is not 
sufficient to cause bone metastases.
Recent studies have proposed a critical contribution of 
cancer stem-like cells to the development of metastases (22). 
CD44 is one of the most well-recognized markers for 
CSCs (2,3). Consistent with this notion, our previous study 
Figure 6. Effects of CD44v8-10 overexpression on the development of bone 
metastases of MDA-MB-231 cells. (A) Representative histological pictures 
of bone metastases (hematoxylin and eosin staining; scale bar, 1 mm). 
(B) Histomorphometric analysis of the tumor burden in bone. Data are 
expressed as tumor area (mm2; n=5/group). (C) Immunohistochemical detec-
tion of panCD44 and CD44v9 expression in cancer cells colonized in bone 
(asterisk, bone; scale bar, 100 µm). CD, cluster of differentiation; CD44v, 
variant isoform of CD44; EV, empty vector; Cl, clone; T, tumor; BM, bone 
marrow; n.s., not significant. 
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demonstrated that CD44s confers stem cell-like phenotypes to 
cancer cells, thus leading to the increased formation of bone 
metastases (16). The present study, using MCF-7 cells, revealed 
that CD44v8-10 also enhanced sphere formation, suggesting 
that CD44v8-10, in addition to CD44s, has the ability to confer 
stem cell-like properties to cancer cells and may be a marker 
for CSCs.
It has been suggested that CD44v is predominantly 
expressed in epithelial cells, whereas CD44s is mainly expressed 
in mesenchymal cells (19). Furthermore, the induction of 
epithelial-mesenchymal transition (EMT) is accompanied 
by a shift from CD44v to CD44s (19). In contrast to these 
findings, Yae et al reported that the expression of the CD44 
isoforms is not associated with that of EMT markers (20). In 
the present study, RT-PCR analysis also revealed that the over-
expression of ESRP1 and CD44v8-10 did not cause consistent 
changes in the expression of the epithelial marker E-cadherin 
or the mesenchymal marker vimentin in cancer cells (data 
not shown). Thus, further studies are required to clarify the 
molecular mechanism of the association between the switch in 
CD44 isoform expression and EMT.
ESRP1 has been demonstrated to regulate the alterna-
tive splicing of genes other than CD44, including fibroblast 
growth factor receptor 2, catenin delta-1 (CTNND1) and 
enabled homolog (ENAH) (18). The current study confirmed 
by RT-PCR analysis that the overexpression of ESRP1 also 
changed the splicing patterns of CTNND1 and ENAH (data 
not shown). The involvement of the ESRP1-induced splicing 
switch in genes other than CD44 requires further investigation.
In conclusion, the present results collectively suggest 
that CD44v8-10 promotes tumor aggressiveness and bone 
metastases to a similar extent to CD44s, while their func-
tional differences have yet to be elucidated in detail. Thus, 
CD44v8-10, in addition to CD44s, could be a potential thera-
peutic target for the treatment of bone metastases.
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